Ultragenyx (RARE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.64B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ultragenyx (RARE) Earnings: Report Dates and Results
Ultragenyx (RARE) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Ultragenyx reported EPS of -$1.16, below the -$1.15 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RARE has an expected report date of Feb 10, 2027.
RARE Earnings Call
The latest RARE earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, RARE beat 13, missed 26 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $173.00M, up 8.1% from $160.00M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.16 | -$1.15 | -$1.25 - $0.75 | -0.87% | Miss | N/A | 6 | 0 up, 1 down | Nov 3, 2026 | $173.00M |
| Jun 30, 2026 | -$0.90 | -$1.27 | N/A | +29.13% | Beat | N/A | 2 | 0 up, 3 down | Aug 4, 2026 | $214.00M |
| Mar 31, 2026 | -$1.54 | -$1.46 | -$2.01 - -$0.78 | -5.48% | Miss | N/A | 11 | 0 up, 2 down | May 5, 2026 | $136.00M |
| Dec 31, 2025 | -$1.29 | -$1.17 | -$1.76 - -$0.71 | -10.26% | Miss | N/A | 12 | 2 up, 1 down | Feb 12, 2026 | $207.28M |
| Sep 30, 2025 | -$1.81 | -$1.21 | -$1.39 - -$0.98 | -49.59% | Miss | N/A | 12 | N/A | Nov 4, 2025 | $160.00M |
| Jun 30, 2025 | -$1.17 | -$1.32 | -$1.41 - -$1.11 | +11.36% | Beat | N/A | 11 | 7 up, 1 down | Aug 5, 2025 | $167.00M |
| Mar 31, 2025 | -$1.57 | -$1.64 | -$2.41 - -$1.18 | +4.27% | Beat | N/A | 10 | 0 up, 1 down | May 6, 2025 | $139.00M |
| Dec 31, 2024 | -$1.39 | -$1.27 | -$1.48 - -$1.01 | -9.45% | Miss | N/A | 11 | 2 up, 0 down | Feb 13, 2025 | $164.65M |
| Sep 30, 2024 | -$1.40 | -$1.47 | -$1.76 - -$0.88 | +4.76% | Beat | N/A | 18 | 1 up, 0 down | Nov 5, 2024 | $139.49M |
| Jun 30, 2024 | -$1.52 | -$1.63 | -$2.13 - -$1.41 | +6.75% | Beat | N/A | 17 | 2 up, 0 down | Aug 1, 2024 | $147.03M |
| Mar 31, 2024 | -$2.03 | -$1.72 | -$2.04 - -$1.39 | -18.02% | Miss | N/A | 18 | 1 up, 0 down | May 2, 2024 | $108.83M |
| Dec 31, 2023 | -$1.52 | -$1.61 | -$2.45 - -$0.71 | +5.59% | Beat | N/A | 16 | 1 up, 0 down | Feb 15, 2024 | $127.14M |
| Sep 30, 2023 | -$2.23 | -$2.01 | -$2.71 - -$1.55 | -10.95% | Miss | N/A | 15 | 1 up, 4 down | Nov 2, 2023 | $98.05M |
| Jun 30, 2023 | -$2.25 | -$2.02 | -$2.32 - -$1.63 | -11.39% | Miss | N/A | 17 | 1 up, 0 down | Aug 3, 2023 | $108.31M |
| Mar 31, 2023 | -$2.33 | -$1.61 | -$2.91 - -$1.55 | -44.72% | Miss | N/A | 17 | 1 up, 0 down | May 4, 2023 | $100.50M |
| Dec 31, 2022 | -$2.19 | -$1.80 | -$3.33 - -$1.60 | -21.67% | Miss | N/A | 17 | 3 up, 0 down | Feb 16, 2023 | $103.35M |
| Sep 30, 2022 | -$3.48 | -$2.40 | -$3.04 - $4.63 | -45.00% | Miss | N/A | 16 | 1 up, 1 down | Nov 2, 2022 | $90.70M |
| Jun 30, 2022 | -$2.12 | -$1.64 | -$2.31 - -$1.22 | -29.27% | Miss | N/A | 16 | 1 up, 0 down | Jul 28, 2022 | $89.34M |
| Mar 31, 2022 | -$2.06 | -$1.78 | -$2.21 - -$1.45 | -15.73% | Miss | N/A | 16 | 1 up, 0 down | May 5, 2022 | $79.94M |
| Dec 31, 2021 | -$1.55 | -$1.19 | -$1.73 - -$0.77 | -30.25% | Miss | N/A | 17 | 3 up, 1 down | Feb 10, 2022 | $83.39M |
| Sep 30, 2021 | -$1.45 | -$1.10 | -$1.83 - -$0.93 | -31.82% | Miss | N/A | 18 | N/A | Nov 2, 2021 | $81.65M |
| Jun 30, 2021 | -$1.35 | -$1.05 | -$2.27 - -$0.97 | -28.57% | Miss | N/A | 16 | N/A | Aug 2, 2021 | $86.97M |
| Mar 31, 2021 | -$1.72 | -$1.29 | -$1.81 - -$0.77 | -33.33% | Miss | N/A | 14 | N/A | May 4, 2021 | $99.39M |
| Dec 31, 2020 | -$1.59 | -$1.14 | -$1.91 - -$0.69 | -39.47% | Miss | N/A | 16 | N/A | Feb 11, 2021 | $91.54M |
| Sep 30, 2020 | -$0.94 | -$1.06 | -$1.75 - -$0.53 | +11.32% | Beat | N/A | 15 | N/A | Oct 27, 2020 | $81.47M |
| Jun 30, 2020 | -$1.14 | -$1.72 | -$1.79 - -$0.82 | +33.72% | Beat | N/A | 16 | N/A | Jul 30, 2020 | $61.71M |
| Mar 31, 2020 | -$2.04 | -$1.68 | -$2.45 - -$1.38 | -21.43% | Miss | N/A | 16 | N/A | May 6, 2020 | $36.31M |
| Dec 31, 2019 | -$1.62 | -$1.53 | -$1.98 - -$1.46 | -5.88% | Miss | N/A | 16 | N/A | Feb 13, 2020 | $35.59M |
| Sep 30, 2019 | -$2.00 | -$1.55 | -$1.97 - -$1.49 | -29.03% | Miss | N/A | 16 | N/A | Nov 5, 2019 | $25.80M |
| Jun 30, 2019 | -$1.90 | -$1.59 | -$1.81 - -$1.45 | -19.50% | Miss | N/A | 16 | N/A | Aug 1, 2019 | $24.15M |
| Mar 31, 2019 | -$1.82 | -$1.67 | -$1.90 - -$1.53 | -8.98% | Miss | N/A | 16 | N/A | May 6, 2019 | $18.17M |
| Dec 31, 2018 | -$1.73 | -$1.79 | -$2.28 - -$1.26 | +3.35% | Beat | N/A | 16 | N/A | Feb 19, 2019 | $16.26M |
| Sep 30, 2018 | -$1.74 | -$1.99 | -$2.15 - -$1.81 | +12.56% | Beat | N/A | 17 | N/A | Nov 5, 2018 | $11.76M |
| Jun 30, 2018 | -$1.87 | -$2.13 | -$2.20 - -$1.92 | +12.21% | Beat | N/A | 17 | N/A | Aug 2, 2018 | $12.79M |
| Mar 31, 2018 | -$2.07 | -$0.87 | -$2.20 - $3.83 | -137.93% | Miss | N/A | 17 | N/A | May 7, 2018 | $10.68M |
| Dec 31, 2017 | -$1.89 | -$1.99 | -$2.26 - -$1.73 | +5.03% | Beat | N/A | 13 | N/A | Feb 20, 2018 | $2.41M |
| Sep 30, 2017 | -$1.87 | -$1.87 | -$1.98 - -$1.67 | 0.00% | In line | N/A | 16 | N/A | Nov 2, 2017 | $198000 |
| Jun 30, 2017 | -$1.72 | -$1.71 | -$1.83 - -$1.59 | -0.58% | Miss | N/A | 14 | N/A | Jul 27, 2017 | N/A |
| Mar 31, 2017 | -$1.63 | -$1.71 | N/A | +4.68% | Beat | N/A | N/A | N/A | May 4, 2017 | N/A |
| Dec 31, 2016 | -$1.75 | -$1.73 | N/A | -1.16% | Miss | N/A | N/A | N/A | Feb 16, 2017 | $5000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$5.84, after -$6.34 the year before. It was -$6.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$5.84 | N/A |
| Dec 31, 2024 | -$6.34 | N/A |
| Dec 31, 2023 | -$8.33 | N/A |
| Dec 31, 2022 | -$9.85 | N/A |
| Dec 31, 2021 | -$6.07 | N/A |
| Dec 31, 2020 | -$5.71 | N/A |
| Dec 31, 2019 | -$7.34 | N/A |
| Dec 31, 2018 | -$7.41 | N/A |
| Dec 31, 2017 | -$7.11 | N/A |
| Dec 31, 2016 | -$6.20 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 19 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,371 | 19 | |
| 2026Q2 | Jun 30, 2026 | 7,434 | 23 | |
| 2026Q1 | Mar 31, 2026 | 8,629 | 21 | |
| 2025Q4 | Dec 31, 2025 | 6,605 | 19 | |
| 2025Q3 | Sep 30, 2025 | 2,480 | 5 | |
| 2025Q2 | Jun 30, 2025 | 7,787 | 23 | |
| 2025Q1 | Mar 31, 2025 | 8,871 | 20 | |
| 2024Q4 | Dec 31, 2024 | 8,783 | 15 |
2026Q3 Earnings Call
Opening remarks
Joshua Higa Chief of Staff and Vice President of Investor Relations Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Howard Horn, Chief Financial Officer; Erik Harris, Chief Commercial Officer; and Eric Crombez, Chief Medical Officer. I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings. I'll now turn the call over to Emil.
Emil Kakkis Chief Executive Officer and President Thanks, Josh, and good afternoon, everyone. The third quarter was a significant one for Ultragenyx in many ways. In August and September, the FDA approved GENGLYCOS for glycogen storage disease type Ia and FAYUVI for Sanfilippo syndrome type A. These approvals are the result of years of work by our teams and the original scientists, as well as the families, patients, and investigators who took part in the studies. We also saw the disappointing data from the GTX-102 Phase 3 that surprised us despite compelling Phase 2 data, which has now necessitated significant reductions across the company. These actions will bring our cost structure in line with our revenue. This enables us to be well positioned to continue commercializing our six products for patients with rare diseases and thoughtfully invest in our development programs, all while becoming a profitable company next year. While the clinical study miss on an important program that could create great value has challenged us, we should recognize all that the company has successfully accomplished in 12 years as a public company. We now have six product approvals for the first-ever treatment indications across multiple treatment modalities and are driving revenue growth globally of about 20% per year for multiple years, adding up to more than $1 billion in revenue and profitability. So while today we acknowledge the setback, when I started the company with $2 million in the secretary, I would have been surprised and inspired to know that we have become a highly respected, admired team of 1,000 professionals treating thousands of patients with rare and ultra-rare diseases worldwide. There is more work to do, and today we will outline the steps we are taking to move the company to its next stage as a profitable company, driving commercialization and development of first-ever treatments for rare diseases. To begin with, I'll focus on the launch of our two new gene therapy products. Both these products provide meaningful and transformative options for these rare disease patients and their families.
Frequently Asked Questions About RARE
When is Ultragenyx's next earnings date?
Ultragenyx's next earnings report is expected for Feb 10, 2027.
Did RARE beat earnings estimates last quarter?
No. Ultragenyx reported EPS of -$1.16 for the quarter ended Sep 30, 2026, below the -$1.15 estimate by 0.87%.
What EPS do analysts expect from RARE next quarter?
The consensus EPS estimate for Ultragenyx for the quarter ending Dec 31, 2026 is -$0.51 from 22 analysts, with estimates from -$1.18 to $3.11.
How often does RARE beat earnings estimates?
Ultragenyx beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -3.86%.
RARE pages: Overview, Earnings, Forecast, Financials, Competitors